From exceptional survival to drug targets.

Cure51 Target ID

Identify and prioritize high-value therapeutic targets using the biology of exceptional cancer survivors.

Our science

DOWNLOAD THE BROCHURE

TALK TO OUR TEAM

accelerate discovery.

Query-driven discovery grounded in deeply matched cohorts and multi-modal molecular profiling.

All biological samples are processed in the Cure51 Central Lab for comprehensive profiling using state-of-the-art technologies.These technologies allow researchers to integrate genomic, transcriptomic, microbial and proteomic data to reveal key survival biomarkers and underlying biology.

12-18 months

gained vs the convetional path to Phase:

Conventional pathway

5-6 years

With Cure51

4 - 4.5 Years

Outliers

Controls

+1000 Patients Samples Biobanked

Genomics, Transcriptomics and Clinical Data

3 Focus Indications: GBM, PDAC & SCLC.

End-to-End Validation Pipeline

EXISTING CURE51 COHORTS

NEW DATA GENERATION

FOR DISCOVERY & DEVELOPMENT

Target ID & validation programs

Ask biological queries against the outlier cohort and receive shortlists of targets that have passed the ultimate biological filter — survival. In-silico and in-vitro validation packages with Cure51's trusted partners.

FOR MARKETED & LATE-STAGE ASSETS

Competitive benchmarking

Partnership models

USE CASES

Cure51's pharma research partnership with Servier.

Our global cohort of exceptional GBM survivors and discovery platform, combined with Servier's R&D and drug-development expertise, to uncover and advance new therapeutic targets.

This partnership combines Cure51’s unique international global cohort of exceptional glioblastoma survivors and proprietary discovery platform with Servier’s R&D and drug-development expertise, aiming to identify and advance new therapeutic targets. It marks Cure51’s first research partnership with a pharmaceutical company, with Cure51 eligible to receive up to €442 million per target in potential milestone payments.

“By combining Cure51’s unique insights derived from exceptional glioblastoma survivors with our deep R&D capabilities, we are uniquely positioned to translate groundbreaking biological mechanisms into potential new therapies for patients.”

Claude Bertrand EVP Research & Development, Servier

Deeply matched survivor and control cohorts

Multi-modal molecular profiling

Query-driven target identification

Target prioritization and validation

CAPABILITIES AND BENEFITS.

`Turning multimodal data into novel drug programs.`

01

HOW IT WORKS.

02

What you achieve  with CURE51 TARGET ID.

Cure51’s Method to Unlock New BiologY.

Analysis of multi‑omics datasets

Proprietary algorithms To identify targets

Integration of partner‑specific constraints

Transparent, data‑driven selection criteria

We eliminate weak hypothesis through a stringent 4-gate in-silico prioritization funnel. This is paired with our “Lab-in-the-Loop” discovery where multi-omics analysis continuously informs automated in-vitro wet lab experiments.

+300 data points / patient

Cure51 has created a unique granular & multimodal single cell dataset.